Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 6 | - | 0,00 % | ||
| BIONTECH | 3 | 13 | +0,44 % | ||
| BIOMARIN PHARMACEUTICAL | 2 | 12 | -2,35 % | ||
| DYNAVAX | 2 | 4 | +38,34 % | ||
| AMICUS THERAPEUTICS | 2 | 1 | -0,83 % | ||
| ULTRAGENYX | 2 | - | -1,37 % | ||
| AUTOLUS THERAPEUTICS | 2 | - | +0,71 % | ||
| INSMED | 1 | 7 | +2,67 % | ||
| GILEAD SCIENCES | 1 | 5 | +0,02 % | ||
| ZEVRA THERAPEUTICS | 1 | 1 | +5,52 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:59 | Praxis Precision Medicines Wins FDA Breakthrough Designation For Essential Tremor Drug | - | RTTNews | ||
| 14:58 | No Christmas present for Sanofi, as FDA turns down MS drug | 1 | pharmaphorum | ||
| 14:46 | Praxis Precision Medicines: FDA erteilt 'Breakthrough'-Status für Medikament gegen essenziellen Tremor | 1 | Investing.com Deutsch | ||
| 14:42 | Bernstein reiterates Gilead Sciences stock rating, citing minimal Medicaid impact | 2 | Investing.com | ||
| 14:42 | KeyBanc maintains Sector Weight rating on Lifecore Biomedical stock | 1 | Investing.com | ||
| 14:36 | Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta | 6 | GlobeNewswire (USA) | ||
| 14:34 | Erfolgreicher Marktstart von Aucatzyl: Needham hebt Kursziel für Autolus an | 2 | Investing.com Deutsch | ||
| 14:34 | Praxis Precision Medicines erhält von FDA "Breakthrough"-Status für Tremor-Medikament | 2 | Investing.com Deutsch | ||
| 14:18 | Needham raises Autolus Therapeutics stock price target on Aucatzyl launch success | 9 | Investing.com | ||
| 14:18 | Genmab A/S: Genmab Portfolio Prioritization Update | 147 | Business Wire | Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher-impact opportunities across Genmab's... ► Artikel lesen | |
| 14:06 | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor | 88 | GlobeNewswire (Europe) | The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA... ► Artikel lesen | |
| 14:06 | ARS Pharmaceuticals, Inc.: neffy (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) | 81 | GlobeNewswire (Europe) | neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (- 30 kg) living with severe allergic reactions Pediatrix Therapeutics- which has... ► Artikel lesen | |
| 13:50 | BIONTECH SE ADR - Jetzt kippt die Ruhe in Bewegung! | 9 | Maximilian Berger | ||
| 13:45 | Ultragenyx Pharmaceutical Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13:36 | Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC) | 36 | GlobeNewswire (Europe) | CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| 13:28 | GENMAB A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13:18 | Praxis Precision Medicines stock price target raised to $843 from $507 at BTIG | 1 | Investing.com | ||
| 13:05 | Praxis Precision Medicines, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12:31 | DYNAVAX TECHNOLOGIES CORP - 8-K, Current Report | 2 | SEC Filings | ||
| 11:09 | OMEROS CORP - 8-K, Current Report | 1 | SEC Filings |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .